目的观察康艾注射液对非霍奇金淋巴瘤(NHL)患者血清血管内皮生长因子(VEGF)水平的影响及其对患者近期疗效、生活质量的影响。方法将85例NHL患者随机分为治疗组和对照组,治疗组采用康艾注射液配合CHOP方案治疗,对照组单用CHOP方案化疗,治疗前后检测患者血清VEGF水平,并评价两组患者的近期疗效、生活质量、毒副反应。结果治疗后治疗组患者血清VEGF水平显著降低(P<0.05),近期疗效有上升趋势,生活质量显著提高(P<0.05),毒副反应明显降低(P<0.05)。

结论康艾注射液可以降低与NHL患者预后有关的血清VEGF水平,配合化疗有明显的增效、减毒及改善患者生活质量的作用。
Objective To observe the influence of Kangai injection on blood serum vascular endothelial growth factor of non-Hodgkin lymphoma patient. And the effect of synergy, attenuation and improving the quality of life of Kangai injection was evaluated. Methods Eighty-five non-Hodgkin lymphoma patients were randomized into treatment group and control group. The patients of the treatment group were treated by injecting Kangai injection and CHOP combined chemotherapy, those of the control group were treated by CHOP combined chemotherapy only. The concentration of vascular endothelial growth factor in blood serum was detected before and after treatment. The curative effect in the near future, quality of life and adverse reaction was evaluated. Results The concentration of vascular endothelial growth factor in blood serum of the patients of the treatment group decreased after therapy(P < 0.05), curative effect in the near future had a tendency of ascensus, the quality of life raised significantly (P < 0.05), adverse reaction of the combined chemotherapy decreased obviously(P < 0.05). Conclusion Kangai injection with CHOP combined chemotherapy has effect of synergy, attenuation and improving the quality of life. And it can decrease the concentration of vascular endothelial growth factor in blood serum of non-Hodgkin lymphoma patient.
【Keyword】：Kangai injection;Vascular endothelial growth factor;Non-Hodgkin lymphoma
非霍奇金淋巴瘤(NHL)是血液系统的恶性肿瘤,近年来发病有上升趋势[1],其对化疗敏感,临床多采用联合化疗,但易产生耐药性或化疗耐受性差而不能给药,影响了疗效。近年来研究表明,中药配合化疗对NHL的治疗有较好的增效减毒作用[2],本组研究采用康艾注射液配合CHOP方案化疗治疗NHL85例,评价其近期疗效、生活质量及毒副反应,并检测患者治疗前后血清血管内皮生长因子(VEGF)水平变化,现报道如下。1资料与方法1.1一般资料85例NHL患者均为2003年至2004年我科住院患者,其中男性50例,女性35例。年龄15～70岁,中位年龄50岁。初治者60例,复治者25例